Corner Office Conversation with Eli Lilly's Global CEO David Ricks
Eli Lilly has launched its obesity and diabetes drug Mounjaro (Tirzepatide) in India. Weight loss drugs, a pharmaceutical segment that has taken the world by storm, has catapulted Eli Lilly to being the world’s most valuable company with a market cap of over $800 billion. In this episode, ET’s Vikas Dandekar and Teena…
We score an episode from what we can actually measure — its reach and engagement, what listeners say about it, and what it covers. We don't have those signals for this one yet, so it doesn't get a number.
Buzzmeter says it's buzzing across platforms — the Hive Vote says whether the people who actually listened liked it.
Rate this episode
Add your vote to the Hive — listeners rate every episode after they finish.
- No reviews yet — be the first.
Similar episodes from other shows
More like The Morning Brief →
Ozempic sparked the weight-loss drug trend. Mounjaro is leading it in India
Dave Ricks, CEO of Eli Lilly, on GLP-1s and the business of pharma
Inside the GLP-1 Gold Rush: Eli Lilly CEO on New Breakthroughs, Addiction & Mental Health, Pricing
Weight Loss Just Got Easier in India?
One great episode in your inbox, daily — free.
One email a day, unsubscribe anytime. No spam, ever.